189 related articles for article (PubMed ID: 28704854)
1. Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors.
Gómez-Peralta F; Abreu C; Mora-Navarro G; López-Morandeira P; Pérez-Gutierrez E; Cordero-García B; Brito-Sanfiel M
Exp Clin Endocrinol Diabetes; 2018 May; 126(5):268-276. PubMed ID: 28704854
[TBL] [Abstract][Full Text] [Related]
2. Glycaemic control in patients with type 2 diabetes switching from premixed insulin to long-acting basal insulin analogue plus oral antidiabetic drugs: an observational study.
Gómez-Peralta F; Carramiñana-Barrera F; Félix-Redondo FJ; Fraile-Gómez J;
Int J Clin Pract; 2012 Oct; 66(10):959-68. PubMed ID: 22994330
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study.
Schiel R; Müller UA
Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):627-33. PubMed ID: 18058596
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Charbonnel B; Schweizer A; Dejager S
Hosp Pract (1995); 2013 Apr; 41(2):93-107. PubMed ID: 23680741
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study.
Schiel R; Müller UA
Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):58-64. PubMed ID: 17973208
[TBL] [Abstract][Full Text] [Related]
6. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice.
Hammer H; Klinge A
Int J Clin Pract; 2007 Dec; 61(12):2009-18. PubMed ID: 17997807
[TBL] [Abstract][Full Text] [Related]
7. A prospective study to optimize insulin treatment by switching to insulin glargine in type 2 diabetic patients previously uncontrolled on premixed insulin: the optimization study.
Yang W; Lv X; Li Q; Jia W; Tian H
Curr Med Res Opin; 2012 Apr; 28(4):533-41. PubMed ID: 22449098
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.
Rosenstock J; Lewin AJ; Norwood P; Somayaji V; Nguyen TT; Teeter JG; Johnson SL; Dai H; Terra SG
Diabet Med; 2011 Apr; 28(4):464-9. PubMed ID: 21392067
[TBL] [Abstract][Full Text] [Related]
10. Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study.
Mathieu C; Storms F; Tits J; Veneman TF; Colin IM
Acta Clin Belg; 2013; 68(1):28-33. PubMed ID: 23627191
[TBL] [Abstract][Full Text] [Related]
11. Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome.
Sicras-Mainar A; Navarro-Artieda R
Diabetes Technol Ther; 2014 Nov; 16(11):722-7. PubMed ID: 25089916
[TBL] [Abstract][Full Text] [Related]
12. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
[TBL] [Abstract][Full Text] [Related]
13. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
Lee SH; Gantz I; Round E; Latham M; O'Neill EA; Ceesay P; Suryawanshi S; Kaufman KD; Engel SS; Lai E
BMC Endocr Disord; 2017 Nov; 17(1):70. PubMed ID: 29110647
[TBL] [Abstract][Full Text] [Related]
15. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
16. [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
Sicras-Mainar A; Navarro-Artieda R
Rev Peru Med Exp Salud Publica; 2014; 31(4):626-34. PubMed ID: 25597711
[TBL] [Abstract][Full Text] [Related]
17. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.
Fadini GP; Albiero M; Menegazzo L; de Kreutzenberg SV; Avogaro A
Diabetes Obes Metab; 2012 Jun; 14(6):518-22. PubMed ID: 22171692
[TBL] [Abstract][Full Text] [Related]
18. Effective switch from premixed to basal-prandial insulin to achieve glycemic goals in type 2 diabetes.
Lavernia F
Postgrad Med; 2010 May; 122(3):28-32. PubMed ID: 20463411
[TBL] [Abstract][Full Text] [Related]
19. Impact of health policy and practice on finding the best fit for patients with type 2 diabetes after metformin failure: Croatian pilot study.
Cigrovski Berković M; Herman Mahečić D; Gradišer M; Bilić-Ćurčić I
Prim Care Diabetes; 2017 Jun; 11(3):265-272. PubMed ID: 28314484
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
Hayashi T; Murayama H; Shinfuku Y; Taniguchi T; Tsumiyama I; Oyama N
Expert Opin Pharmacother; 2020 Jan; 21(1):121-130. PubMed ID: 31689132
[No Abstract] [Full Text] [Related]
[Next] [New Search]
